Related Experiment Video
Updated: Jan 9, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Rational antipsychotic polypharmacy in psychotic and bipolar disorders: A focus on D2 receptor partial agonists
1(Corresponding author) Behavioral Health Clinical Pharmacy Specialist, Montefiore Nyack Hospital, Nyack, New York, salwana@montefiorenyack.org.
Abstract:
Aripiprazole, brexpiprazole, and cariprazine have a unique pharmacology as demonstrated by their high affinity to the dopamine type-2 receptor (ie, D2 receptor). These agents may be preferred over others for the treatment of psychotic and bipolar disorders due to their lower incidence of movement disorders and sedation. When prescribed adjunctively to full antagonist agents, partial agonist antipsychotics can mitigate adverse effects such as hyperprolactinemia. However, their high affinity for the D2 receptor may interfere with the efficacy of full antagonist antipsychotics when used in combination. Some partial agonists may be less preferred in particular patient scenarios based on their demonstrated clinical efficacy. Three illustrative patient cases highlight clinical pearls related to the safe and effective use of antipsychotic polypharmacy involving partial agonist antipsychotics.
Related Concept Videos
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Typical and Atypical Agents
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Mania and Antimanic Drugs: Overview
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

